University of California San Francisco,
SSI2023 | 49th Annual Meeting and Summer School of the Scandinavian Society for Immunology
University of California San Francisco,
Title: RNA Circuits in immune responses
Title: Molecular mechanisms controlling miRNA homeostasis
Dr. Ansel is an RNA Immunologist studying how post-transcriptional regulation shapes immune responses through network regulation of gene expression circuitry in lymphocytes and other immune cells. Ansel lab projects span from technology development and basic mechanisms of RNA regulation through in vivo function of miRNAs, lncRNAs and RNA binding proteins in mice and human cells.
University of Bergen,
Title: Single cell proteomics provide insights into autoimmune disorders
Silke Appel is Professor of Immunology at the Broegelmann Research Laboratory and Head of the Core facility for flow cytometry at the Department of Clinical Science, University of Bergen. Her current research is focused on single cell network profiling of immune cells in order to stratify patients with autoimmune diseases such as Sjögren’s syndrome and psoriasis.
Sonoma Therapeutics & University of California San Francisco, USA
Title: Immunotherapy: Building a bridge to a cure for type 1 diabetes
Jeffrey Bluestone is A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and Director of the Hormone Research Institute in the Diabetes Center. His research over the past 25 years has focused on understanding the basic processes that control T cell activation and immune tolerance in autoimmunity and organ transplantation. During the last several years, his research has adapted the animal studies using biologics and cell based therapies to develop therapeutics that can be used in humans with autoimmunity and under conditions of allotransplant rejection. Since 2010 Dr. Bluestone is the executive vice chancellor and provost at the University of California San Francisco (UCSF) serving as chief academic officer guiding the research and academic enterprise advancing the campus priorities in close collaboration with the chancellor and the campus leadership teams, and to oversee the campus ethics and compliance enterprise. Previously he served in a number of posts including Director of theUCSF Diabetes Center, as Director of the Immune Tolerance Network. Through his 30-year scientific career, he has authored more than 300 peer-reviewed publications that include prominent papers in Nature, Nature Immunology, and the Journal of Immunology and Diabetes. He has received numerous accolades for his work, including his 2006 election to the American Academy of Arts and Sciences, the Mary Tyler Moore & Robert Levine Excellence in Clinical Research Award from the Juvenile Diabetes Research Foundation, and the distinguished alumni award from the Cornell Graduate School of Medical Science.
Title: Neuroinflammation associated with inborn errors of immunity.
Yenan Bryceson is professor at the Department of Medicine, Huddinge, Karolinska Institutet. Currently Bryceson laboratory is based at the Center for Hematology and Regenerative Medicine (HERM) at Karolinska University Hospital, Huddinge, and employs a wide range of techniques. His work strives to understand the role of lymphocyte cytotoxicity in health and disease, and ultimately harness their potent activity to fight cancer. Yenan Bryceson group has developed methods for quantification of human cytotoxic lymphocyte development and function, uncovering key mechanisms for their differentiation and cytotoxic activity. They hope that outcomes of their work will include fundamentally new conceptualizations of immunological disorders, basic immunological and genetic insights, and potent, specific immunotherapeutic interventions for treatment of disease.
Title: Forward and Reverse Translation: Lessons from successful and unsuccessful therapies
Dr. Andrew Chan is Senior Vice President of Research-Biology at Genentech, Inc where he oversees biological research across all therapeutic areas including oncology, immunology, neuroscience, infectious diseases and regenerative medicine. He is a leader in biotherapeutics discovery and development and integrates lessons learned about disease pathogenesis and mechanisms of therapy. Chan’s research focuses on how our immune systems protect us against foreign pathogens and yet cause autoimmune and inflammatory diseases. Chan is also co-inventor of ocrelizumab (Ocrevus™), the first B-cell directed therapy approved by the FDA for treatment of both relapsing and progressive forms of multiple sclerosis.
Title: Single-cell analysis reveals new insights on T cell effector functions in rheumatic diseases
Dr. K. Chemin received her PhD from the University of Paris with Dr. JC. Bories in 2006. She did her post-doctoral trainings at the Curie Institute, Paris with Dr. C. Hivroz and at the Karolinska Institute, Stockholm with Prof. V. Malmström. Since 2021, she is an associate professor (docent, Immunology) at the Center for Molecular Medicine at the Karolinska Institute, Stockholm. Her research focuses on the characterisation of T cells and their persistency at the site of inflammation in the autoimmune diseases rheumatoid arthritis and myositis.
Cecilia Dominguez Conde
Human Technopole, Milan,
Title: Single-cell genomics to study developmental immunology
Cecilia Domínguez Conde is a Group Leader at the Population & Medical Genomics programme of the Genomics Centre. After training as a pharmacist in the University of Seville, Cecilia went on to do a PhD in Immunology at the Research Centre for Molecular Medicine (CeMM) in Vienna where her work focused on dissecting the genetic cause of molecularly undiagnosed primary immunodeficiencies using exome sequencing. In 2019 Cecilia joined the Teichmann lab at the Wellcome Sanger Institute where her focus has been to dissect the diversity of human immune cell types across lymphoid and non-lymphoid tissues as part of the Human Cell Atlas initiative. Her research group at HT uses cutting-edge genomic technologies to study developmental immunology.
University of Turku,
Title: Computational approaches for Single-cell omics
Laura Elo, PhD, is Professor of Computational Medicine and Head of Medical Bioinformatics Centre at University of Turku, Finland. She has PhD in applied mathematics and long experience in molecular systems immunology and application of machine learning in medical research in several research projects (e.g. ERC). Her research group (https://elolab.utu.fi) develops statistical and machine learning methods to interpret large-scale molecular and clinical data, and applies the novel methods to enable new discoveries in human T cell regulation and new understanding about the development of human immune-mediated diseases, such as the autoimmune type 1 diabetes. She has published >150 research articles and >20 software packages.
Queen Mary University of London,
Title: The immunopathogenesis of multiple sclerosis: new insights exposed by disease-modifying therapies
Gavin Giovannoni is an academic neurologist based in the Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London. His current research is focused on the Epstein-Barr virus as a possible cause of multiple sclerosis, MS-related neurodegeneration, biomarker discovery & validation, and MS clinical outcomes.
La Jolla Institute for Immunology,
Title: Transcriptional control of CD8+ T cell exhaustion in cancer
Dr Patrick Hogan received his PhD from Harvard University, and conducted research for many years at Harvard Medical School and its affiliated Immune Disease Institute. He is now a Professor at the La Jolla Institute for Immunology and a Member of Moores Cancer Center at the University of California–San Diego. He is known for his work defining the calcium-calcineurin-NFAT transcriptional pathway in T cells and elucidating the molecular mechanisms of STIM-ORAI-dependent calcium signalling. His laboratory is currently investigating the transcriptional basis for ‘exhaustion’ in tumor-infiltrating lymphocytes.
Title: Proteogenomics for precision immunotherapy in cancer
Janne Lehtiö has MSc from Helsinki University, Finland and PhD in engineering at Royal Institute of Technology (KTH) in Stockholm, Sweden. Post the PhD, Lehtiö worked in biotech industry before returning to academia to Karolinska Institutet, Sweden. In 2015, he was selected to faculty Professor position at Karolinska Institutet and since 2021 holds shared clinical professor position at Karolinska univ. hospital. Lehtiö is a visiting professor at InFlames program at University of Turku, Finland. Lehtiö-lab’s focus on protegenomics, systems biology and cancer precision medicine, from techdevelopment to clinical applications on lung, breast cancer and leukaemia research.
University of Turku,
Title: Single-cell omics to understand immune mediated diseases
Dr. Tapio Lönnberg is a research group leader at the Turku Bioscience Centre and the InFLAMES Research Flagship at the University of Turku, Finland. He is a pioneer in the use of single-cell transcriptomics in immunology and head of the Single Cell Omics core unit at the Turku Bioscience Centre. His current research leverages single-cell sequencing and spatial transcriptomics in the study of primary immune cell populations in health and disease, with a particular focus on arthritic and cardiovascular diseases. His lab investigates the molecular mechanisms that regulate the differentiation and cellular crosstalk of leukocyte populations, aiming to identify core gene modules that are associated with disease states, and which can be exploited for more efficient diagnosis, patient stratification, and therapies.
University of Turku,
Title: Single-cell analysis of macrophage heterogeneity
Dr Alexander Mildner studied Biology in Göttingen, Germany. He absolved his PhD in the laboratory of Prof Marco Prinz investigating the origin of Microglia. During his PostDoc in the lab of Prof Steffen Jung at the Weizmann Institute in Israel he examined the differentiation of monocytes and dendritic cells. As a Principal Investigator with a Heisenberg fellowship at the MDC in Berlin, his research focuses on the identification of pathogenic myeloid cells during neuroinflammation and lung diseases. Now Alexander Mildner is an Associate Professor for Immunology in Turku. He was selected as a highly cited researcher between 2020-2022.
La Jolla Institute for Immunology
Title: TET methylcytosine dioxygenases, cancer and autoimmune/inflammatory disease
Dr. Anjana Rao obtained her Ph.D. in Biophysics from Harvard University and was a Professor at Harvard Medical School until 2011, when she moved to the La Jolla Institute and UCSD (University of California in San Diego). Her research is focused on the regulation of gene expression, using immune cells, haematopoietic stem cells and embryonic stem cells as model systems. Her lab purified and molecularly characterized the calcium/ calcineurin-regulated transcription factor NFAT; defined diverse transcriptional programs regulated by NFAT proteins in T cells; identified the pore subunit of the store-operated Ca2+ channel, ORAI1; and discovered that proteins of the TET family are enzymes that mediate DNA demethylation and regulate gene expression by oxidizing 5-methylcytosine. In recent studies, her lab has defined the role of NFAT and other transcription factors in anti-tumor responses, and explored the roles of TET proteins and oxidized methylcytosines in the immune/ haematopoietic systems and in embryonic development and oncogenesis. Dr. Rao is an elected member/fellow of the US National Academy of Sciences, the American Academy of Arts and Sciences and the American Association for the Advancement of Science.
University College London,
Title: Fine-tuning costimulation blockade in autoimmunity
Lucy Walker is Professor of Immune Regulation at the UCL Institute for Immunity & Transplantation. She has a longstanding interest in immune regulation with a particular focus on how CTLA-4 and CD28 operate to control T cell immunity. Her group aims to understand the pathways that regulate the development of autoimmune diseases, like type 1 diabetes, with the ultimate goal of developing new immunotherapies. Lucy has served as Panel Chair for several funding bodies including the MRC, the Wellcome Trust and NC3Rs. She received a Royal Society Wolfson Research Merit Award in 2015 and an EFIS Lecture Award in 2016.